BRAF Mutation and Its Importance in Colorectal Cancer | IntechOpen
Frequencies of RAS/BRAFV600E mutation subtypes. N = 152 (KRAS Exon2... | Download Scientific Diagram
Cancers | Free Full-Text | Targeting BRAF and RAS in Colorectal Cancer
Cells | Free Full-Text | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer | Modern Pathology
Overview of molecular biomarkers in metastatic colorectal cancer. WT,... | Download Scientific Diagram
Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers | Discover Oncology
Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review - Benoist Chibaudel, Christophe Tournigand, Franck Bonnetain, Hubert Richa, Magdalena Benetkiewicz, Thierry André, Aimery de Gramont, 2015
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020 | Published in healthbook TIMES Oncology Hematology
BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer | Scientific Reports
Frontiers | Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer | Nature Medicine
Molecular targeted therapy of BRAF-mutant colorectal cancer - Michel Ducreux, Ali Chamseddine, Pierre Laurent-Puig, Cristina Smolenschi, Antoine Hollebecque, Peggy Dartigues, Emmanuelle Samallin, Valérie Boige, David Malka, Maximiliano Gelli, 2019
Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness | OTT
PANDA study demonstrates progression-free survival gain for FOLFOX + panitumumab and 5FU / LV + first-line panitumumab to RAS-BRAF wild-type elderly metastatic colorectal cancer patients - Onco Americas
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Kaplan-Meier curves for colorectal cancer patients with BRAF-wild-type... | Download Scientific Diagram
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer | Cancer Cell International | Full Text
Personalized Medicine in Oncology - <em>BRAF</em> Mutation in Colorectal Cancer<br> <h4>Anita Turk, MD; Dustin Deming, MD<br>Division of Hematology and Oncology,Department of Medicine<br>University of Wisconsin-Madison School of Medicine and Public ...
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer
Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI
Factors affecting treatment selection in RAS/BRAF wild-type... | Download Scientific Diagram
Frontiers | Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
